MedTrace Logo

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

NCT06026410 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-14

No results posted yet for this study

Summary

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

Conditions

  • Solid Tumors With HRAS Alterations
  • Non Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)
  • Renal Cell Carcinoma (Kidney Cancer)
  • Non Clear Cell Renal Cell Carcinoma (nccRCC)

Interventions

DRUG

Darlifarnib

Oral administration

DRUG

Cabozantinib

Oral administration

DRUG

Adagrasib

Oral administration

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    collaborator INDUSTRY

  • Kura Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-18
Primary Completion
2027-01-31
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06026410 on ClinicalTrials.gov